IL320004A - שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן - Google Patents
שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגןInfo
- Publication number
- IL320004A IL320004A IL320004A IL32000425A IL320004A IL 320004 A IL320004 A IL 320004A IL 320004 A IL320004 A IL 320004A IL 32000425 A IL32000425 A IL 32000425A IL 320004 A IL320004 A IL 320004A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- kit
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263413475P | 2022-10-05 | 2022-10-05 | |
| PCT/US2023/034454 WO2024076626A1 (en) | 2022-10-05 | 2023-10-04 | Methods of treating estrogen receptor-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320004A true IL320004A (he) | 2025-06-01 |
Family
ID=90608897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320004A IL320004A (he) | 2022-10-05 | 2023-10-04 | שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4598520A1 (he) |
| JP (1) | JP2025533900A (he) |
| KR (1) | KR20250095627A (he) |
| CN (1) | CN120187424A (he) |
| AU (1) | AU2023356291A1 (he) |
| IL (1) | IL320004A (he) |
| MX (1) | MX2025004050A (he) |
| WO (1) | WO2024076626A1 (he) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138659A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| EP2434891B9 (en) * | 2009-05-27 | 2021-05-05 | PTC Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| EP3355884B1 (en) * | 2015-10-01 | 2021-04-28 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
| CN113490850B (zh) * | 2018-08-17 | 2024-12-06 | 基因泰克公司 | 用于治疗乳腺癌的诊断和治疗方法 |
| WO2021178846A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
-
2023
- 2023-10-04 IL IL320004A patent/IL320004A/he unknown
- 2023-10-04 WO PCT/US2023/034454 patent/WO2024076626A1/en not_active Ceased
- 2023-10-04 CN CN202380071326.0A patent/CN120187424A/zh active Pending
- 2023-10-04 JP JP2025520010A patent/JP2025533900A/ja active Pending
- 2023-10-04 EP EP23875477.4A patent/EP4598520A1/en active Pending
- 2023-10-04 AU AU2023356291A patent/AU2023356291A1/en active Pending
- 2023-10-04 KR KR1020257014629A patent/KR20250095627A/ko active Pending
-
2025
- 2025-04-04 MX MX2025004050A patent/MX2025004050A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120187424A (zh) | 2025-06-20 |
| MX2025004050A (es) | 2025-05-02 |
| EP4598520A1 (en) | 2025-08-13 |
| AU2023356291A1 (en) | 2025-04-17 |
| JP2025533900A (ja) | 2025-10-09 |
| KR20250095627A (ko) | 2025-06-26 |
| WO2024076626A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10765684B2 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
| Fan et al. | PERK, beyond an unfolded protein response sensor in estrogen-induced apoptosis in endocrine-resistant breast cancer | |
| RU2018133298A (ru) | Способы применения агонистов fxr | |
| US8853188B2 (en) | Compositions and methods for cancer treatment | |
| WO2008004798A8 (en) | Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | |
| IL320452A (he) | טיפול משולב עבור סרטן הערמונית | |
| US20160113925A1 (en) | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors | |
| US20110190244A1 (en) | Method of treatment of egfr inhibitor toxicity | |
| CN109562080A (zh) | 用于治疗癌症和癌症并发症的药物组合物 | |
| RU2004137801A (ru) | Композиция для терапии рака сапонинами или сапогенинами | |
| IL320004A (he) | שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן | |
| CN102441168B (zh) | 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用 | |
| JPWO2008139952A1 (ja) | 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤 | |
| Guo et al. | Estrogen Receptor α (ERα)-targeting compounds and derivatives: Recent advances in structural modification and bioactivity | |
| RU2025111136A (ru) | Способы лечения опосредованных рецептором эстрогена нарушений | |
| RU2010140888A (ru) | Улучшенные противораковые терапии | |
| MXPA04005771A (es) | Composicion de estrogeno y de otras hormonas con ascorbato, lisina, prolina y otras substancias. | |
| WO2020175922A3 (ko) | 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 | |
| US20240366562A1 (en) | Gynecomastia and/or mastalgia treatment | |
| TW200902028A (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases | |
| CN117956986A (zh) | 男性乳房发育症和/或乳腺痛治疗 | |
| AU2012200290B2 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
| US9907797B2 (en) | Combination therapies for overcoming resistance to mitotic agents during chemotherapy | |
| AU2006303878B2 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
| Starr | PACIFIC: Practice-Changing Study in Stage III Unresectable Non-Small-Cell Lung Cancer. |